ELI LILLY & Co: directors' dealings · United States · SEC (Form 4)

About ELI LILLY & Co

Eli Lilly and Company (NYSE: LLY) is a major U.S.-listed pharmaceutical company headquartered in Indianapolis, Indiana, United States. The company traces its origins to 1876, when Colonel Eli Lilly founded a drug manufacturing business in Indianapolis; Lilly was then incorporated in Indiana in 1901 to succeed that enterprise. Today, Lilly reports in a single operating segment: human pharmaceutical products. Its business model is built around research, development, manufacturing, and global commercialization of innovative medicines. ([investor.lilly.com](https://investor.lilly.com/static-files/84711071-9e5a-47e1-bc74-d0753a2d93a8)) From an equity analysis perspective, Lilly’s portfolio is now dominated by cardiometabolic growth engines, while also retaining meaningful exposure to oncology, immunology, and other specialty therapeutic areas. Key marketed products include Mounjaro and Zepbound, which have become core growth drivers, alongside Trulicity, Humalog, Verzenio, Taltz, Jardiance through a collaboration, Jaypirca, and other assets. The company’s pipeline is also closely watched, especially orforglipron, its oral GLP-1 candidate that has become one of the most strategically important programs in the industry. ([investor.lilly.com](https://investor.lilly.com/static-files/84711071-9e5a-47e1-bc74-d0753a2d93a8)) In competitive terms, Lilly is one of the global leaders in incretin-based therapies, competing in a highly contested market with Novo Nordisk and other pharmaceutical peers. Its competitive edge comes from strong clinical execution, a broad late-stage pipeline, manufacturing scale, and a commercial footprint that has allowed it to capture substantial demand in diabetes and obesity. Lilly’s 2024 annual report indicates that Mounjaro, Trulicity, and Zepbound together represented a very large share of total revenue, underscoring how central the cardiometabolic franchise has become to the investment case. ([investor.lilly.com](https://investor.lilly.com/static-files/84711071-9e5a-47e1-bc74-d0753a2d93a8)) Geographically, Lilly has a global presence with sales in the United States and outside the United States, and it continues to invest across major developed markets and selected high-growth regions. Recent company news has reinforced the growth narrative: in 2025 and 2026, Lilly reported multiple positive clinical and regulatory milestones for orforglipron, expanded access and pricing initiatives for Zepbound, and label expansion progress for Jaypirca. Taken together, these developments support the view of Lilly as a high-quality large-cap healthcare franchise with secular growth drivers, strong innovation momentum, and an increasingly important position in global metabolic medicine. ([investor.lilly.com](https://investor.lilly.com/news-releases/news-release-details/zepbound-tirzepatide-most-prescribed-weight-management?utm_source=openai))